. Author manuscript; available in PMC: 2026 Jul 15.

Published in final edited form as: Arthritis Care Res (Hoboken). 2025 Dec 10;78(4):469–477. doi: 10.1002/acr.25647

Table 2:

The Potential Effect of Race-Specific vs Race-Neutral PFT Reference Equations on Care Delivery.

	Eligibility for clinical trials enrollment N (%)			Initiation of immunosuppression N (%)			Referral for lung transplant N (%)
Equation	NHANES III	GLI 2012	GLI Global	NHANES III	GLI 2012	GLI Global	NHANES III	GLI 2012	GLI Global
All (N=3,550)	1,449 (41)	1,367 (39)	1,226 (35)	908 (26)	844 (24)	805 (23)	168 (5)	161 (5)	160 (5)
White (N=2,909)	1,100 (38)	1,000 (34)	783 (27)	660 (23)	585 (20)	449 (15)	115 (4)	102 (4)	69 (2)
Black (N=641)	349 (54)	367 (57)	443 (69)	248 (39)	259 (40)	356 (56)	53 (8)	59 (9)	91 (14)

This table demonstrates the numbers and percentages of individuals who meet three clinical criteria with each of the equations (NHANES III, GLI 2012, and GLI Global). Eligibility for clinical trials (SLS I/SLS II) is defined by ppFVC<80% and ppFVC≥45%, initiation of immunosuppression by ppFVC<70%, and referral for lung transplant by ppFVC≤50%. All p-values from McNemar tests comparing the proportions of individuals who meet each clinical criteria for each race when using race-specific (NHANES III and GLI 2012) and race-neutral (GLI Global) equations were <0.0001.